Sharon Applin had all the organs in her pelvis removed and wants her experience to aid other patients.
A cancer patient who had to have all the organs within her pelvis removed is at the centre of a research project designed to improve future treatments.
Ms Applin, who was previously treated successfully for a skin cancer in 2020, started experiencing bleeding, diarrhoea and severe pain last year. "[It was] explained very clearly that without major surgery I had only six months to a year to live," Ms Applin said. "I need to make sure I have my stoma bags stocked up just in case of an emergency and a change of clothes in case of any leaks... this is a mental strain all the time and has changed my life.""Being involved has helped me come to terms with what I have had done, what I have been through, and to understand how pelvic exenteration is done," she said.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'We need to normalise conversations about cancer and life after cancer'Mum-of-three Tracey is on a mission to help improve conversations about cancer after being treated for womb cancer
Read more »
Trajectory of fear of cancer recurrence levels six to 18 months post-breast cancer diagnosisResearchers examined the predictors of fear of cancer recurrence (FCR) and its trajectory among breast cancer (BC) patients.
Read more »
Researchers discover possible new treatment for triple-negative breast cancerZachary Schug, Ph.D., assistant professor in the Molecular and Cellular Oncogenesis Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute, has published a new paper in the journal Nature Cancer. Schug's paper, titled 'Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer,' demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer. Schug's research shows how silencing a certain gene, ACSS2, may improve existing treatments for patients.
Read more »
New CAR T cell therapy approach minimizes severe side effectsIn recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients' T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer.
Read more »